Aktis Oncology (NASDAQ:AKTS) Trading 7.7% Higher – Here’s Why

Posted by Brian Himes on Aug 26th, 2026

Aktis Oncology (NASDAQ:AKTS – Get Free Report) traded up 7.7% on Monday . The company traded as high as $25.07 and last traded at $25.92. 344,579 shares were traded during trading, an increase of 3% from the average session volume of 334,544 shares. The stock had previously closed at $24.07.

Wall Street Analyst Weigh In

AKTS has been the subject of a number of recent research reports. Raymond James Financial assumed coverage on Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. BMO Capital Markets started coverage on Aktis Oncology in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target on the stock. Wedbush began coverage on Aktis Oncology in a research report on Wednesday, August 19th. They issued an “outperform” rating and a $35.00 price target on the stock. Wall Street Zen lowered Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Finally, William Blair initiated coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Aktis Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

View Our Latest Research Report on Aktis Oncology

Aktis Oncology Stock Performance

The stock has a market cap of $1.43 billion and a price-to-earnings ratio of -32.55. The firm’s 50-day simple moving average is $25.68 and its two-hundred day simple moving average is $21.37.

Aktis Oncology (NASDAQ:AKTS – Get Free Report) last announced its earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The firm had revenue of $3.38 million for the quarter, compared to the consensus estimate of $2.70 million. Equities research analysts expect that Aktis Oncology will post -1.8 earnings per share for the current fiscal year.

Insider Transactions at Aktis Oncology

In other Aktis Oncology news, Director Ken Herrmann sold 4,856 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the transaction, the director directly owned 3,506 shares in the company, valued at approximately $86,107.36. This trade represents a 58.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Institutional Investors Weigh In On Aktis Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in AKTS. State of Wyoming acquired a new stake in Aktis Oncology in the second quarter worth $32,000. The Manufacturers Life Insurance Company grew its holdings in shares of Aktis Oncology by 2.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company’s stock valued at $1,548,000 after buying an additional 1,051 shares during the period. Bank of America Corp DE increased its position in shares of Aktis Oncology by 4.2% in the 2nd quarter. Bank of America Corp DE now owns 72,835 shares of the technology company’s stock valued at $2,347,000 after buying an additional 2,909 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Aktis Oncology by 14.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company’s stock valued at $1,587,000 after buying an additional 6,349 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in Aktis Oncology by 49.3% during the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after buying an additional 6,942 shares during the period. Institutional investors own 28.84% of the company’s stock.

About Aktis Oncology

(Get Free Report)

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.